全文获取类型
收费全文 | 46895篇 |
免费 | 3927篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 375篇 |
儿科学 | 1908篇 |
妇产科学 | 1293篇 |
基础医学 | 6742篇 |
口腔科学 | 971篇 |
临床医学 | 6481篇 |
内科学 | 9132篇 |
皮肤病学 | 894篇 |
神经病学 | 4800篇 |
特种医学 | 1074篇 |
外科学 | 4105篇 |
综合类 | 406篇 |
一般理论 | 62篇 |
预防医学 | 5758篇 |
眼科学 | 671篇 |
药学 | 2638篇 |
2篇 | |
中国医学 | 54篇 |
肿瘤学 | 3566篇 |
出版年
2024年 | 60篇 |
2023年 | 421篇 |
2022年 | 582篇 |
2021年 | 1263篇 |
2020年 | 938篇 |
2019年 | 1396篇 |
2018年 | 1530篇 |
2017年 | 1202篇 |
2016年 | 1330篇 |
2015年 | 1398篇 |
2014年 | 1782篇 |
2013年 | 2619篇 |
2012年 | 3653篇 |
2011年 | 3768篇 |
2010年 | 2066篇 |
2009年 | 1831篇 |
2008年 | 3048篇 |
2007年 | 3134篇 |
2006年 | 3079篇 |
2005年 | 2898篇 |
2004年 | 2808篇 |
2003年 | 2575篇 |
2002年 | 2316篇 |
2001年 | 361篇 |
2000年 | 259篇 |
1999年 | 312篇 |
1998年 | 522篇 |
1997年 | 391篇 |
1996年 | 347篇 |
1995年 | 338篇 |
1994年 | 267篇 |
1993年 | 269篇 |
1992年 | 185篇 |
1991年 | 159篇 |
1990年 | 144篇 |
1989年 | 111篇 |
1988年 | 124篇 |
1987年 | 87篇 |
1986年 | 93篇 |
1985年 | 97篇 |
1984年 | 100篇 |
1983年 | 100篇 |
1982年 | 127篇 |
1981年 | 123篇 |
1980年 | 103篇 |
1979年 | 62篇 |
1978年 | 66篇 |
1977年 | 49篇 |
1976年 | 45篇 |
1972年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Understanding the minimum clinically important difference: a review of concepts and methods. 总被引:2,自引:0,他引:2
Anne G Copay Brian R Subach Steven D Glassman David W Polly Thomas C Schuler 《The spine journal》2007,7(5):541-546
BACKGROUND CONTEXT: The effectiveness of spinal surgery as a treatment option is currently evaluated through the assessment of patient-reported outcomes (PROs). The minimum clinically important difference (MCID) represents the smallest improvement considered worthwhile by a patient. The concept of an MCID is offered as the new standard for determining effectiveness of a given treatment and describing patient satisfaction in reference to that treatment. PURPOSE: Our goal is to review the various definitions of MCID and the methods available to determine MCID. STUDY DESIGN: The primary means of determining the MCID for a specific treatment are divided into anchor-based and distribution-based methods. Each method is further subdivided and examined in detail. METHODS: The overall limitations of the MCID concept are first identified. The basic assumptions, statistical biases, and shortcomings of each method are examined in detail. RESULTS: Each method of determining the MCID has specific shortcomings. Three general limitations in the accurate determination of an MCID have been identified: the multiplicity of MCID determinations, the loss of the patient's perspective, and the relationship between pretreatment baseline and posttreatment change scores. CONCLUSIONS: An ideal means of determining the MCID for a given intervention is yet to be determined. It is possible to develop a useful method provided that the assumptions and methodology are initially declared. Our efforts toward the establishment of a MCID will rely on the establishment of specific external criteria based on the symptoms of the patient and treatment intervention being evaluated. 相似文献
52.
Acta Endoscopica - C’est un test de sélection. C’est un outil important de communication et d’information, c’est dire si elle doit être connue, comprise et bien... 相似文献
53.
Annie Mathieu Stéphanie Mazza Dominique Petit Anne Décary Jessica Massicotte-Marquez Jacques Malo Jacques Montplaisir 《Clinical neurophysiology》2007,118(7):1538-1544
OBJECTIVE: The aim of this study was to determine whether EEG slowing is more pronounced in older than younger OSAS patients and to verify whether this cortical slowing is correlated to daytime performance, respiratory perturbation and sleep fragmentation. METHODS: Twelve young OSAS patients (mean age 38.2+/-2.0 y) and 13 older OSAS patients (mean age 62.2+/-1.9 y) along with 13 young controls (mean age 35.8+/-2.0 y) and 14 older controls (mean age 60.2+/-2.0 y) underwent a polysomnographic evaluation followed by a waking EEG recording. As a global index of cortical slowing, a ratio of slow-to-fast frequencies was calculated in all cortical regions. Daytime performance was assessed using the four choice reaction time test. RESULTS: Differences in waking EEG and in daytime performance were analyzed by ANOVAs with Group and Age as factors. Waking EEG did not yield a Group by Age interaction. OSAS patients had higher ratios across all regions than controls. Similarly, daytime performance revealed no Group by Age interaction. However, OSAS patients showed more lapses than controls and older subjects were slower than younger subjects. CONCLUSIONS: Our results indicate that age does not interact with OSAS to worsen the severity of cortical slowing, but age can add to the OSAS effect to worsen daytime performance deficits in OSAS patients. SIGNIFICANCE: The daytime performance deficits observed particularly in elderly OSAS patients warrant a careful clinical assessment of these patients to prevent accidents and injuries. 相似文献
54.
Sylvia J T Jansen Wilma Otten Anne M Stiggelbout 《Journal of clinical oncology》2004,22(15):3181-3190
PURPOSE: Many studies have determined cancer patients' preferences for adjuvant therapy, for example, by asking patients the extent of benefit they would need in order to accept the therapy. However, little is known about the determinants that influence these preferences. Our research goal was to explore which determinants underlie patients' preferences by means of a literature review. METHODS: PubMed searches were conducted to identify studies in which cancer patients' preferences for adjuvant therapy had been elicited by means of a treatment preference instrument. Twenty-three papers were evaluated with regard to reported relationships between preferences and potential determinants. A total of 40 determinants were recorded and classified into one of seven categories: (1) treatment-related determinants, (2) sociodemographic characteristics and current quality of life, (3) clinical characteristics, (4) measurement instrument-related determinants, (5) time-related determinants, (6) cognitive/affective determinants, and (7) specialist-related determinants. Results: The benefit and toxicity of treatment, experience of the treatment, and having dependents (eg, children) living at home were important determinants of patients' preferences. Furthermore, qualitative data suggested that cognitive/affective and specialist-related determinants might have a large impact on patients' treatment preferences. CONCLUSION: Our results show that patients' preferences cannot fully be explained on the basis of treatment-related determinants and patient and clinical characteristics. More research is needed in the area of cognitive/affective and specialist-related determinants because of the lack of quantitative results. Furthermore, we recommend carrying out larger studies in which the (internal) relationships between determinants and preferences are assessed in the context of a cognitive cost-benefit model. 相似文献
55.
Anne?Helene?Garde ?se?Marie?Hansen Johnni?Hansen 《International archives of occupational and environmental health》2009,82(10):1219-1228
Background
Sleep problems are common effects of shift work. The aim of the present study was to evaluate how different types of shift affect sleep and sleepiness, and to relate sleepiness to urinary 6-sulfatoxymelatonin. 相似文献56.
OBJECTIVE: Based on recent safety and efficacy data, combined with the known pharmacokinetic parameters of aminoglycosides in the newborn, once-daily gentamicin should be preferable to the many other dosing regimens currently in use. Although there are growing data to support its use in term newborns, experience with preterm infants is more limited. In our Neonatal Intensive Care Unit, we experienced difficulties regarding complicated dosing regimens, actual dosing errors, and the tendency to check trough and peak levels around the third dose for infants receiving only a 48 hour course. Therefore, we conducted a quality improvement initiative in which we developed and tested a clinical practice guideline for the use of once-daily gentamicin for preterm and term infants that we hoped would yield trough and peak levels in our target range. METHODS: We combined a review of the published English language literature with pharmacokinetic analysis of our own data prior to initiation of this new regimen to design the following dosing regimen: <35 weeks gestation: 3 mg/kg q 24 hours, > or =35 weeks gestation: 4 mg/kg q 24 hours. Our goal serum levels were a trough < or =2 microg/ml and a peak between 6 and 12 microg/ml. We collected and analyzed trough and peak levels from all infants receiving this dosing regimen in the first week of life for at least 72 hours between 3/1/99 and 12/31/00. RESULTS: In total, 214 babies met our inclusion criteria, 75 of whom were <35 weeks gestation. 100% of babies of all gestational ages had a nontoxic trough level. For infants <35 weeks gestation, 79% had a therapeutic peak level, with a mean value of 6.8 microg/ml. For infants of at least 35 weeks gestation, 93% had a therapeutic peak level, with a mean value of 8.4 microg/ml. 92% of nontherapeutic peaks were too low. CONCLUSION: This study of once-daily gentamicin represents the largest sample size of pre-term infants published to date. The proposed regimen is simple and yields a high proportion of desirable levels. We recommend it for use in preterm and term newborns. 相似文献
57.
Anne A. Lawrence 《Archives of sexual behavior》2009,38(6):1050-1056
58.
59.
Chronic obstructive pulmonary disease is one of the most significant chronic illnesses of adults. Comprehensive care of the affected patient requires the medical-surgical nurse to have knowledge of the disease process, collaborative management, and nursing care based on research and current practice guidelines. 相似文献
60.
Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice 总被引:2,自引:0,他引:2
Anne Bourson Véronique Kapps Catherine Zwingelstein Alain Rudler Frank G. Boess A. J. Sleight 《Naunyn-Schmiedeberg's archives of pharmacology》1997,356(6):820-826
Audiogenic seizures can be induced in DBA/2J mice following intense auditory stimulation. A number of neurotransmitters, including
5-hydroxytryptamine (5-HT), are believed to be involved in mediating this effect since it has been shown previously that depletion
of 5-HT or blockade of 5-HT receptors protects DBA/2J mice from these audiogenic seizures. The present study was undertaken
to determine whether antagonism of the newly identified 5-HT7 receptor may protect DBA/2J mice from audiogenic seizures by attempting to correlate in vivo potency of compounds with their
affinity at the 5-HT7 receptor. All compounds used in the correlation were shown to be antagonists at the 5-HT7 receptor and a statistically significant correlation was observed between 5-HT7 affinity and doses for half-maximal response (ED50) for protection of DBA/2J mice from sound-induced seizures (r = 0.80; P < 0.05). No significant correlation was observed between in vivo activity and affinity at either 5-HT1A, 5-HT2A or 5-HT2C receptors. It is also unlikely that interactions between the 5-ht5 receptor will protect DBA/2J mice from audiogenic seizures since metergoline and mesulergine which are both active in this
in vivo model have no affinity for the 5-ht5 receptor. There are similarities between the pharmacology of the 5-HT7 receptor and that of the 5-HT1A receptor, however the correlation between the in vivo potency in DBA/2J mice and 5-HT1A affinity was not significant. Furthermore, the 5-HT1A receptor antagonist WAY 100135 did not protect DBA/2J mice from audiogenic seizures at doses that antagonise 5-HT1A receptor-mediated effects in mice. These data suggest that antagonism of 5-HT7 receptors may protect against audiogenic seizures in DBA/2J mice although a definitive conclusion must await studies with
selective 5-HT7 antagonists.
Received: 20 March 1997 / Accepted: 10 August 1997 相似文献